Abstracts Archive - Page 971 of 2425 - ACR Meeting Abstracts

Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Chakkarin Burudpakdee ³, Lawrence Chang ², Jing He ⁴ and Mark Genovese ⁵, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Falls Church, VA, ⁴IQVIA, Plymouth meeting, PA, ⁵Stanford University, Stanford, CA
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
Abstract Number: 251 • 2019 ACR/ARP Annual Meeting
Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
Dylan Mezzio ¹, Edward Li² and Sanjeev Balu ³, ¹Xcenda, Pleasant Hill, CA, ²Sandoz Inc., Princeton, NJ, ³Sandoz Inc, Princeton, NJ
Background/Purpose: Biosimilars have enabled some US institutions and payers to achieve significant financial savings after implementing a formulary change from the reference biologic. However, within…
Abstract Number: 252 • 2019 ACR/ARP Annual Meeting
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Aliza Karpes ¹, Zhigang Duan ², Hui Zhao ², Lincy Lal ³, Wenyaw Chan ³, Maria E. Suárez-Almazor ⁴, Sharon Giordano ², John Swint ³ and Maria Lopez-Olivo², ¹School of Public Health, The University of Texas Health Science Center at Houston, Dallas, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: To evaluate the sequences of therapeutic drugs used by rheumatoid arthritis (RA) patients whose initial tumor necrosis factor inhibitor (TNFi) therapy failed, as well…
Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 254 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population
Joe Zhuo¹, Ying Bao ², Qian Xia ², Aarti Rao ³, Chidananda Samal ³ and Sonie Lama ⁴, ¹Bristol-Myers Squibb, Princeton, NJ, ²Bristol-Myers Squibb, Lawrenceville, NJ, ³Mu Sigma, Bangalore, India, ⁴BMS, Lawrenceville, NJ
Background/Purpose: Interstitial lung disease (ILD) is a frequent extraarticular manifestation of rheumatoid arthritis (RA) that imposes substantial economic burden on patients and healthcare systems. However,…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…
Abstract Number: 256 • 2019 ACR/ARP Annual Meeting
Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States
Debbie Ehrmann Feldman¹ and Richard Nahin ², ¹University of Montreal, Montreal, QC, Canada, ²National Center for Complementary and Integrative Health, National Institutes of Health, Bethesda, MD
Background/Purpose: Chronic musculoskeletal pain can affect up to 20% of persons under the age of 25 and is a risk factor for persistent chronic musculoskeletal…
Abstract Number: 257 • 2019 ACR/ARP Annual Meeting
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Jasvinder Singh¹ and john Cleveland ², ¹University of Alabama Medical Center, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Alcohol abuse and associated mortality is an important public health problem in the U.S. To our knowledge, limited data are available on alcohol use…
Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Geyanne Lui¹, Mangala Rajan ¹, Lisa Kern ¹, Laura Pinheiro ¹, Monika Safford ¹, Jeffrey Curtis ² and Iris Navarro-Millan ¹, ¹Weill Cornell Medicine, New York, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 260 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014
Shraddha Jatwani¹, Karan Jatwani ² and Karan Chugh ¹, ¹St. Vincent Evansville, Evansville, ²Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Venous thromboembolism (VTE) is a major health problem and can be potentially fatal when complicated by lethal pulmonary embolism (PE). Previous hospital-based studies have…
Abstract Number: 261 • 2019 ACR/ARP Annual Meeting
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh ¹, Bikramjit Bindra ² and Karan Jatwani ³, ¹St. Vincent Evansville, Evansville, ²Government Medical College & Hospital, Chandigarh, India, ³Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
Abstract Number: 262 • 2019 ACR/ARP Annual Meeting
Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)
Caitrin Coffey¹, Avneek Singh Sandhu ², Cynthia Crowson ³, Dennis Asante ¹, Eric Matteson ⁴, Thomas Osborn ⁵, Kenneth Warrington ⁶ and Ashima Makol ⁵, ¹Mayo Clinic, Rochester, MN, ²kettering health, dayton, OH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder which results in multi-organ dysfunction and high morbidity and mortality. There is limited data on healthcare…
Abstract Number: 263 • 2019 ACR/ARP Annual Meeting
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
Laure Gossec¹, Anna Moltó ², Catherine Beauvais ³, Eric Senbel ⁴, René-Marc Flipo ⁵, Sophie Pouplin ⁶, Christophe Richez ⁷, Alain Saraux ⁸, Philippe Gaudin ⁹, Daniel WENDLING ¹⁰ and Maxime Dougados ¹¹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Paris St Antoine University Hospital, Paris, France, ⁴Rheumtologist Private Practice, Marseille, France, ⁵University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France, ⁶Rouen University Hospital, Rouen, France, ⁷Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ⁸CHU de la Cavale-Blanche Brest, Brest, France, ⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ¹⁰Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ¹¹Cochin Hospital, Paris, France
Background/Purpose: In chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis, spondyloarthritis, connective tissue diseases and crystal-induced arthritis, long-term adherence to disease-modifying drugs (DMARDs) is only…
Abstract Number: 264 • 2019 ACR/ARP Annual Meeting
Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
Uta Kiltz¹, Aylin Celik ², Styliani Tsiami ¹, Björn Bühring ², Xenofon Baraliakos ³ and Jürgen Braun ⁴, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) are known to have an increased risk of infections compared to the general population. Therefore, prevention of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].